TPO and autoimmune thrombocytopenic purpura: It is reported that sensitizers can improve the initial response to TPO‐RA in ITP patients by increasing the levels of transforming growth factor‐β (TGF‐β) and tumor necrosis factor‐α (TNF‐α), and a significant increase in tissue biomarkers of TGF‐β can be detected in paraffin lung samples from COVID‐19 patients [7, 15].